Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Shareholder Meeting (May 2021)

18 slides from Fresenius SE & Co. KGaA's shareholder meeting presentation, May 21, 2021

  1. Slide 1: Annual General Meeting – Fresenius SE & Co. KGaA

    Annual General Meeting – Fresenius SE & Co. KGaA May 21, 2021

  2. Slide 2: Welcome!

    Welcome! Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 2

  3. Slide 3: In battle against the coronavirus

    In battle against the coronavirus Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 3

  4. Slide 4: Acquisition of Eugin Group

    Acquisition of Eugin Group Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 4

  5. Slide 5: Acquisition of additional hospitals

    Acquisition of additional hospitals Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 5

  6. Slide 6: Expanding and advancing home dialysis

    Expanding and advancing home dialysis Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 6

  7. Slide 7: Submission for second biosimilar

    Submission for second biosimilar Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 7

  8. Slide 8: Advancing sustainability

    Advancing sustainability Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 8

  9. Slide 9: Significant restrictions due to COVID-19

    Significant restrictions due to COVID-19 Fewer elective Excess mortality procedures among dialysis patients Decreased demand Cuts in project for drugs business Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 9

  10. Slide 10: Stable sales and earnings development

    Stable sales and earnings development Sales EBIT Net income Mio € +5% +0% -3% 36,277 1,879 35,409 4,688 4,612 1,796 2015 2016 2019 2020 2019 2020 2019 2020 2019 2020 Constant currency growth rates; EBIT and net income before special items Annual General Meeting | May 21, 2021 | © Fresenius SE & Co.

  11. Slide 11: 28th consecutive dividend increase proposed

    28th consecutive dividend increase proposed 0.88 0.84 0.80 15% 0.75 CAGR 0.62 0.55 0.44 € 0.42 0.37 0.32 0.29 0.25 0.22 0.23 0.02 1993 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2020: Proposal Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 11

  12. Slide 12: Group outlook 2021: growth despite continuing challenges

    Group outlook 2021: growth despite continuing challenges Sales growth low- to mid-single digit constant currency percentage rate Net income growth constant currency at least broadly stable Before special items; inclusive of anticipated COVID-19 effects Annual General Meeting | May 21, 2021 | © Frese

  13. Slide 13: Medium-term 2020-23 targets confirmed

    Medium-term 2020-23 targets confirmed +4 to +7% Average annual sales growth organic +5 to +9% Average annual earnings growth organic plus ~1% small to mid-size acquisitions Before special items Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 13

  14. Slide 14: Strategic roadmap: medium-term

    Strategic roadmap: medium-term 3 Accelerate • Significant cost savings • Ongoing strategic evaluation 2 Grow • • • Launch Idacio in US Balance sheet flexibility Value creating capital allocation • First meaningful cost savings • Growth areas: Biosimilars, Fertility, Digital • Ongoing strategic evalu

  15. Slide 15: Initiatives to increase efficiency and profitability

    Initiatives to increase efficiency and profitability Purchasing & Clustering Service functions Capacity adjustments New offers Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 15

  16. Slide 16: New areas of growth

    New areas of growth Biosimilars Digital offers Fertility treatments Home dialysis Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 16

  17. Slide 17: Our commitment: Ever better medicine for ever more people

    Our commitment: Ever better medicine for ever more people Annual General Meeting | May 21, 2021 | © Fresenius SE & Co. KGaA 17

  18. Slide 18: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

Fresenius SE & Co. KGaA — Shareholder Meeting (May 2021) on 6ix